Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Huyabio Presents Positive Phase 2a Results for HBI-3000 in Atrial Fibrillation
Details : HBI-3000 (Sulcardine Sulfate) is a multi-ion channel blocker, it inhibits INa-Peak, INa-Late, ICa,L, and IKr, with dominant effects on late sodium current (INa-L) to reduce proarrhythmic risks.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 24, 2025
Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tucidinostat,Nivolumab
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
HUYABIO Shares Positive Phase 2 Data On HBI-8000 and Nivolumab for Melanoma
Details : HBI-8000 (chidamide) is a class I HDAC inhibitor, in combination with nivolumab is being evaluated for the treatment of anti-PD(L)1-naive advanced melanoma.
Product Name : Hiyasta
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 08, 2024
Lead Product(s) : Tucidinostat,Nivolumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
Details : HBI-2438 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lung Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 03, 2022
Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Huyabio International Announces Initiation Of Hbi-3000 Phase 2 Trial
Details : The drug's preclinical and clinical pharmacology supports the potential of HBI-3000 (sulcardine sulfate) to restore sinus rhythm in Atrial Fibrillation. The drug has demonstrated a low risk for proarrhythmia in preclinical testing.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 14, 2022
Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The drug’s preclinical and clinical pharmacology supports the potential of HBI-3000 to restore sinus rhythm in Atrial Fibrillation. The drug has demonstrated a low risk for proarrhythmia in preclinical testing.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 17, 2022
Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HBI-2376 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 20, 2021
Lead Product(s) : Tucidinostat
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of HBI-8000 (Tucidinostat) With Pembrolizumab in Non-Small Cell Lung Cancer
Details : HBI-8000 is a Cytotoxic Drug drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 02, 2021
Lead Product(s) : Tucidinostat
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Chidamide
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Shenzhen Chipscreen Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data from the registration study of HBI-8000 has demonstrated clinically meaningful responses despite the advanced stage of disease and acceptable safety profile to address an important unmet medical need in this patient population.
Product Name : Undisclosed
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
November 30, 2021
Lead Product(s) : Chidamide
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Shenzhen Chipscreen Biosciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tucidinostat
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
HUYABIO International Launches Hiyasta as Monotherapy for Adult T-cell Leukemia/Lymphoma in Japan
Details : Hiyasta (HBI-8000) is an epigenetic immunomodulator approved for the treatment of lymphoma and metastatic breast cancer. it targets class I histone deacetylases and suppresses expression of viral oncogene HTLV-I bZIP factor, NF-kB and the inflammasome in...
Product Name : Hiyasta
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 19, 2021
Lead Product(s) : Tucidinostat
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HBI-2376
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Genhouse Bio
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : HBI-2376 is an oral small molecule inhibitor of SHP2 for multiple tumor types whose cellular growth is dependent on MAPK pathway. Both in vitro and in vivo studies HBI-2376 has shown a very good PK and safety profile.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 31, 2021
Lead Product(s) : HBI-2376
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Genhouse Bio
Deal Size : Inapplicable
Deal Type : Inapplicable